HK1218506A1 - 治療黑素瘤的方法 - Google Patents

治療黑素瘤的方法 Download PDF

Info

Publication number
HK1218506A1
HK1218506A1 HK16106468.2A HK16106468A HK1218506A1 HK 1218506 A1 HK1218506 A1 HK 1218506A1 HK 16106468 A HK16106468 A HK 16106468A HK 1218506 A1 HK1218506 A1 HK 1218506A1
Authority
HK
Hong Kong
Prior art keywords
methods
treating melanoma
melanoma
treating
taxane
Prior art date
Application number
HK16106468.2A
Other languages
English (en)
Chinese (zh)
Inventor
‧德賽
N‧P‧德赛
‧雷恩施樂
M‧雷恩施乐
Original Assignee
阿布拉科斯生物科学有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/791,841 external-priority patent/US9149455B2/en
Application filed by 阿布拉科斯生物科学有限公司 filed Critical 阿布拉科斯生物科学有限公司
Publication of HK1218506A1 publication Critical patent/HK1218506A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5169—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
HK16106468.2A 2013-02-11 2013-12-03 治療黑素瘤的方法 HK1218506A1 (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361763391P 2013-02-11 2013-02-11
US61/763,391 2013-02-11
US13/791,841 2013-03-08
US13/791,841 US9149455B2 (en) 2012-11-09 2013-03-08 Methods of treating melanoma
PCT/US2013/072877 WO2014123612A1 (en) 2013-02-11 2013-12-03 Methods of treating melanoma

Publications (1)

Publication Number Publication Date
HK1218506A1 true HK1218506A1 (zh) 2017-02-24

Family

ID=51300036

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16106468.2A HK1218506A1 (zh) 2013-02-11 2013-12-03 治療黑素瘤的方法

Country Status (13)

Country Link
EP (1) EP2953622B1 (https=)
JP (3) JP6388880B2 (https=)
KR (1) KR102148551B1 (https=)
CN (2) CN105120859B (https=)
BR (1) BR112015019064A8 (https=)
CA (1) CA2900668A1 (https=)
ES (1) ES2872328T3 (https=)
HK (1) HK1218506A1 (https=)
IL (1) IL240388B (https=)
MX (1) MX377729B (https=)
NZ (1) NZ630239A (https=)
WO (1) WO2014123612A1 (https=)
ZA (1) ZA201505956B (https=)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3141245A1 (en) 2010-03-29 2017-03-15 Abraxis BioScience, LLC Methods of treating cancer
MX2012011155A (es) 2010-03-29 2012-12-05 Abraxis Bioscience Llc Metodos para mejorar suministros de farmacos y efectividad de agentes terapeuticos.
AU2012253571A1 (en) 2011-05-09 2014-01-09 Mayo Foundation For Medical Education And Research Cancer treatments
EP3560486A1 (en) 2011-12-14 2019-10-30 Abraxis BioScience, LLC Use of polymeric excipients for lyophilization or freezing of particles
US10413606B2 (en) 2012-10-01 2019-09-17 Mayo Foundation For Medical Education And Research Methods for treating cancer with nanoparticle complexes of albumin-bound paclitaxel and anti-VEGF antibodies
US9149455B2 (en) 2012-11-09 2015-10-06 Abraxis Bioscience, Llc Methods of treating melanoma
US9511046B2 (en) 2013-01-11 2016-12-06 Abraxis Bioscience, Llc Methods of treating pancreatic cancer
EP3698784A1 (en) 2013-03-12 2020-08-26 Abraxis BioScience, LLC Methods of treating lung cancer
RU2015143490A (ru) 2013-03-14 2017-04-26 АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи Способы лечения рака мочевого пузыря
WO2015095842A2 (en) 2013-12-20 2015-06-25 Biomed Valley Discoveries, Inc. Methods and compositions for treating non-erk mapk pathway inhibitor-resistant cancers
KR20170020371A (ko) 2014-06-16 2017-02-22 메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치 골수종의 치료
US9446148B2 (en) 2014-10-06 2016-09-20 Mayo Foundation For Medical Education And Research Carrier-antibody compositions and methods of making and using the same
CR20170031A (es) * 2014-10-06 2017-05-22 Mayo Found For Medical Educaction And Res Composiciones de portador-anticuerpo y métodos para realizarlas y utilizarlas
US10527604B1 (en) 2015-03-05 2020-01-07 Abraxis Bioscience, Llc Methods of assessing suitability of use of pharmaceutical compositions of albumin and paclitaxel
US10705070B1 (en) 2015-03-05 2020-07-07 Abraxis Bioscience, Llc Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug
ES3009356T3 (en) 2015-06-29 2025-03-26 Abraxis Bioscience Llc Nanoparticles comprising sirolimus and an albumin for use in treating epithelioid cell tumors
TW201707725A (zh) 2015-08-18 2017-03-01 美國馬友醫藥教育研究基金會 載體－抗體組合物及其製造及使用方法
JP6921802B2 (ja) * 2015-08-18 2021-08-18 マヨ ファウンデーション フォー メディカル エデュケーション アンド リサーチＭａｙｏ Ｆｏｕｎｄａｔｉｏｎ Ｆｏｒ Ｍｅｄｉｃａｌ Ｅｄｕｃａｔｉｏｎ Ａｎｄ Ｒｅｓｅａｒｃｈ キャリア結合剤組成物およびそれを作製および使用する方法
TW201713360A (en) 2015-10-06 2017-04-16 Mayo Foundation Methods of treating cancer using compositions of antibodies and carrier proteins
WO2017120501A1 (en) 2016-01-07 2017-07-13 Mayo Foundation For Medical Education And Research Methods of treating cancer with interferon
WO2017139698A1 (en) 2016-02-12 2017-08-17 Mayo Foundation For Medical Education And Research Hematologic cancer treatments
EP3432928A4 (en) 2016-03-21 2019-11-20 Mayo Foundation for Medical Education and Research PROCESS FOR IMPROVING THE THERAPEUTIC INDEX FOR CHEMOTHERAPEUTIC
EP3432926A4 (en) 2016-03-21 2019-11-20 Mayo Foundation for Medical Education and Research METHOD FOR REDUCING THE TOXICITY OF CHEMOTHERAPEUTICS
US10618969B2 (en) 2016-04-06 2020-04-14 Mayo Foundation For Medical Education And Research Carrier-binding agent compositions and methods of making and using the same
JP2019526579A (ja) 2016-09-01 2019-09-19 マヨ ファウンデーション フォー メディカル エデュケーション アンド リサーチＭａｙｏ Ｆｏｕｎｄａｔｉｏｎ Ｆｏｒ Ｍｅｄｉｃａｌ Ｅｄｕｃａｔｉｏｎ Ａｎｄ Ｒｅｓｅａｒｃｈ Ｔ細胞癌を標的とする為の方法及び組成物
WO2018045239A1 (en) * 2016-09-01 2018-03-08 Mayo Foundation For Medical Education And Research Carrier-pd-l1 binding agent compositions for treating cancers
RU2021128415A (ru) 2016-09-06 2021-11-08 Мэйо Фаундейшн Фор Медикал Эдьюкейшн Энд Рисерч Композиции с паклитакселом, альбумином и связывающим средством и способы их применения и получения
EP3509635A1 (en) 2016-09-06 2019-07-17 Vavotar Life Sciences LLC Methods of treating triple-negative breast cancer using compositions of antibodies and carrier proteins
KR20230011473A (ko) 2016-09-06 2023-01-20 메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치 Ｐｄ－ｌ１ 발현 암의 치료 방법
KR20250057947A (ko) 2017-10-03 2025-04-29 크리티테크, 인크. 암의 치료를 위한 면역치료제의 전신 전달과 조합된 항신생물성 입자의 국소 전달
IL277402B1 (en) 2018-03-20 2026-04-01 Abraxis Bioscience Llc Methods for treating central nervous system disorders using administration of MTOR inhibitor nanoparticles and albumin
BR112022007710A2 (pt) 2019-10-28 2022-07-12 Abraxis Bioscience Llc Composições farmacêuticas de albumina e rapamicina

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5916596A (en) 1993-02-22 1999-06-29 Vivorx Pharmaceuticals, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US6749868B1 (en) 1993-02-22 2004-06-15 American Bioscience, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US6537579B1 (en) 1993-02-22 2003-03-25 American Bioscience, Inc. Compositions and methods for administration of pharmacologically active compounds
US6096331A (en) 1993-02-22 2000-08-01 Vivorx Pharmaceuticals, Inc. Methods and compositions useful for administration of chemotherapeutic agents
CA2509365C (en) 2002-12-09 2012-08-07 American Bioscience, Inc. Compositions and methods of delivery of pharmacological agents
US20070166388A1 (en) * 2005-02-18 2007-07-19 Desai Neil P Combinations and modes of administration of therapeutic agents and combination therapy
KR20070114753A (ko) * 2005-02-18 2007-12-04 아브락시스 바이오사이언스 인크. 치료제의 조합 및 투여 방식, 및 조합 요법
US8735394B2 (en) * 2005-02-18 2014-05-27 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
EP3527202A1 (en) 2005-08-31 2019-08-21 Abraxis BioScience, LLC Compositions and methods for preparation of poorly water soluble drugs with increased stability
EP2094268A2 (en) * 2006-05-26 2009-09-02 Bayer HealthCare, LLC Drug combinations with substituted diaryl ureas for the treatment of cancer
US20100166869A1 (en) 2007-05-03 2010-07-01 Desai Neil P Methods and compositions for treating pulmonary hypertension
CA2746129A1 (en) * 2008-12-11 2010-06-17 Abraxis Bioscience, Llc Combination chemotherapy of nanoparticulate taxanes and inhibitors of pro-survival and/or inflammatory signals
US20130281376A1 (en) * 2010-10-08 2013-10-24 Abraxis Bioscience, Llc Sparc microenvironment signature, plasma sparc, and ldh as prognostic biomarkers in the treatment of cancer

Also Published As

Publication number Publication date
IL240388B (en) 2020-07-30
ZA201505956B (en) 2016-11-30
NZ630239A (en) 2017-08-25
JP2016513097A (ja) 2016-05-12
CN105120859A (zh) 2015-12-02
ES2872328T3 (es) 2021-11-02
KR20150119177A (ko) 2015-10-23
MX377729B (es) 2025-03-11
EP2953622A4 (en) 2016-09-21
CN109200031A (zh) 2019-01-15
JP6470381B2 (ja) 2019-02-13
EP2953622B1 (en) 2021-03-24
IL240388A0 (en) 2015-09-24
BR112015019064A2 (pt) 2017-07-18
JP2019056014A (ja) 2019-04-11
MX2015010312A (es) 2015-11-18
EP2953622A1 (en) 2015-12-16
KR102148551B1 (ko) 2020-08-26
WO2014123612A1 (en) 2014-08-14
JP6388880B2 (ja) 2018-09-12
CN105120859B (zh) 2018-10-09
JP2018016660A (ja) 2018-02-01
BR112015019064A8 (pt) 2019-11-12
CA2900668A1 (en) 2014-08-14

Similar Documents

Publication Publication Date Title
HK1218506A1 (zh) 治療黑素瘤的方法
HK1216853A1 (zh) 治療胰腺癌的方法
WO2015073587A3 (en) Synthetic membrane-receiver complexes
HK1220980A1 (zh) 用於治疗庞贝氏症的方法和组合物
WO2015066452A3 (en) Methods of treating pediatric cancers
HK1216083A1 (zh) 经动脉的药物递送
CA2900779C (en) Compositions and methods for treating neurodegenerative diseases and cardiomyopathy
WO2013177187A3 (en) Synergistic tumor treatment with extended-pk il-2 and therapeutic agents
CA2900335C (en) Synthetic analogs of epipolythiodioxopiperazines and uses thereof
HK1219231A1 (zh) 治疗儿童实体瘤的方法
GB201314917D0 (en) Treated Tobacco and processes for preparing the same, Devices including the same and uses thereof
MX2014011134A (es) Compuestos de carbamato y preparacion y uso de los mismos.
WO2014165090A8 (en) Compounds for the treatment of tuberculosis
NZ628294A (en) Compositions and methods of use of phorbol esters for the treatment of stroke
WO2014153030A3 (en) Methods of treating cancer and preventing cancer drug resistance
EP3166643A4 (en) Amphiphilic peptide nanoparticles for use as hydrophobic drug carriers and antibacterial agents
WO2015066302A3 (en) Compositions, methods of use, and methods of treatment
PT3079476T (pt) Complexos de cobre-zinco-amónio solubilizados em ácido, composições, preparações, métodos e utilizações
EP3004396A4 (en) Methods and compositions for the treatment of cancer
MX2016013894A (es) Composicion para el cuidado del cuero cabelludo.
AU2018253600A1 (en) Dosage forms and therapeutic uses of l-4-chlorokynurenine
AU2017267955B2 (en) Reduced oxygen carriers and their use for the treatment of carboxyhemoglobinemia
MY178960A (en) Hiv treatment formulation of atazanavir and cobicistat
EP3089745A4 (en) Compounds, compositions, and methods for the treatment of cancers
MX2015013755A (es) Formulacion farmaceutica para uso en el tratamiento y/o prevencion de restenosis.